Part of Thermo Fisher Scientific
Assay-Ready MGC cDNA maximizes the number of authentic overexpression screening hits, dramatically accelerating the discovery of new drug targets
HUNTSVILLE, Ala.,—April 19, 2006—Open Biosystems, Inc., focused on the commercialization of leading-edge life science research tools for drug discovery, today announced the availability of Assay-Ready Complementary DNA (cDNA) based on the industry gold standard Mammalian Gene Collection (MGC). This is the first fully sequenced collection of cDNAs in assay-ready format that is commercially available to the research community and pharmaceutical industry for genome-scale overexpression screening.
Unlike other lyophilized cDNA plate sets, Open Biosystems’ collection minimizes false screening results. Fully sequenced clones ensure the accurate identification of a gene transcript, thereby generating authentic screening hits that do not require verification by sequencing the full clone insert. Sequencing clones is expensive and time-consuming and by providing assay-ready, fully sequenced cDNA, Open Biosystems significantly accelerates the discovery of drug targets that will lead to better diagnosis and treatment of disease.
Open Biosystems’ Assay-Ready MGC cDNA collection is available as a set of 92, 384-well, microplates containing 6,415 human and 9,624 mouse cDNAs in duplicate. This allows researchers and scientists to immediately begin the screening process, avoiding bacterial cultures, plasmid preps, normalization, aliquotting and lyophilization.
“Overexpression with cDNA is a powerful approach to analyzing gene function that, until recently, has been overlooked by researchers,” said Troy Moore, CTO of Open Biosystems. “Our Assay-Ready MGC cDNA offering opens a new realm of possibility for both academic and commercial life science research. With our fully sequenced cDNA plate sets, researchers can more quickly and cost-effectively discover the genes underlying disease that may be targeted by therapeutics. This coupled with our Expression Arrest product line and Open Access RNAi program underscores our commitment to promoting the flow of research-driven tools and technology to advance medical research.”
About Open Biosystems
Open Biosystems, Inc. develops, manufactures and markets genomic research tools to scientists and researchers in corporate, academic and government laboratories. These research tools provide investigators with standardized high-quality genes, RNAi and antibodies for interrogating gene function in relation to oncology, neuroscience and metabolic disorders. Founded in 2001, Open Biosystems is headquartered in Huntsville, Alabama.
